

Lisa C Lindesmith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2187312/publications.pdf>

Version: 2024-02-01

59
papers

7,012
citations

117625

34
h-index

133252

59
g-index

62
all docs

62
docs citations

62
times ranked

5953
citing authors

#	ARTICLE	IF	CITATIONS
1	Norwalk virus: How infectious is it?. <i>Journal of Medical Virology</i> , 2008, 80, 1468-1476.	5.0	1,019
2	Human susceptibility and resistance to Norwalk virus infection. <i>Nature Medicine</i> , 2003, 9, 548-553.	30.7	956
3	Mechanisms of GII.4 Norovirus Persistence in Human Populations. <i>PLoS Medicine</i> , 2008, 5, e31.	8.4	486
4	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	12.6	459
5	Binding of Norwalk Virus-Like Particles to ABH Histo-Blood Group Antigens Is Blocked by Antisera from Infected Human Volunteers or Experimentally Vaccinated Mice. <i>Journal of Virology</i> , 2002, 76, 12335-12343.	3.4	256
6	Norovirus Infectivity in Humans and Persistence in Water. <i>Applied and Environmental Microbiology</i> , 2011, 77, 6884-6888.	3.1	248
7	Immunogenetic Mechanisms Driving Norovirus GII.4 Antigenic Variation. <i>PLoS Pathogens</i> , 2012, 8, e1002705.	4.7	242
8	Cellular and Humoral Immunity following Snow Mountain Virus Challenge. <i>Journal of Virology</i> , 2005, 79, 2900-2909.	3.4	236
9	Viral shape-shifting: norovirus evasion of the human immune system. <i>Nature Reviews Microbiology</i> , 2010, 8, 231-241.	28.6	236
10	Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. <i>Immunological Reviews</i> , 2008, 225, 190-211.	6.0	200
11	Emergence of New Pandemic GII.4 Sydney Norovirus Strain Correlates With Escape From Herd Immunity. <i>Journal of Infectious Diseases</i> , 2013, 208, 1877-1887.	4.0	151
12	Norovirus GII.4 Strain Antigenic Variation. <i>Journal of Virology</i> , 2011, 85, 231-242.	3.4	148
13	Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice. <i>Science</i> , 2021, 373, 991-998.	12.6	144
14	Emergence of a Norovirus GII.4 Strain Correlates with Changes in Evolving Blockade Epitopes. <i>Journal of Virology</i> , 2013, 87, 2803-2813.	3.4	140
15	Genetic Mapping of a Highly Variable Norovirus GII.4 Blockade Epitope: Potential Role in Escape from Human Herd Immunity. <i>Journal of Virology</i> , 2012, 86, 1214-1226.	3.4	139
16	Heterotypic Humoral and Cellular Immune Responses following Norwalk Virus Infection. <i>Journal of Virology</i> , 2010, 84, 1800-1815.	3.4	125
17	Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. <i>Vaccine</i> , 2006, 24, 5220-5234.	3.8	124
18	Broad Blockade Antibody Responses in Human Volunteers after Immunization with a Multivalent Norovirus VLP Candidate Vaccine: Immunological Analyses from a Phase I Clinical Trial. <i>PLoS Medicine</i> , 2015, 12, e1001807.	8.4	119

#	ARTICLE	IF	CITATIONS
19	Monoclonal Antibody-Based Antigenic Mapping of Norovirus GII.4-2002. <i>Journal of Virology</i> , 2012, 86, 873-883.	3.4	113
20	Norovirus Immunity and the Great Escape. <i>PLoS Pathogens</i> , 2012, 8, e1002921.	4.7	110
21	Herd Immunity to GII.4 Noroviruses Is Supported by Outbreak Patient Sera. <i>Journal of Virology</i> , 2009, 83, 5363-5374.	3.4	92
22	Expression and Self-Assembly of Norwalk Virus Capsid Protein from Venezuelan Equine Encephalitis Virus Replicons. <i>Journal of Virology</i> , 2002, 76, 3023-3030.	3.4	91
23	Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: Engineering a recombination-resistant genome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12546-12551.	7.1	84
24	The State of Norovirus Vaccines. <i>Clinical Infectious Diseases</i> , 2014, 58, 1746-1752.	5.8	73
25	Vaccination-induced herd immunity: Successes and challenges. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 64-66.	2.9	73
26	Sera Antibody Repertoire Analyses Reveal Mechanisms of Broad and Pandemic Strain Neutralizing Responses after Human Norovirus Vaccination. <i>Immunity</i> , 2019, 50, 1530-1541.e8.	14.3	71
27	Alphavirus-Adjuvanted Norovirus-Like Particle Vaccines: Heterologous, Humoral, and Mucosal Immune Responses Protect against Murine Norovirus Challenge. <i>Journal of Virology</i> , 2009, 83, 3212-3227.	3.4	62
28	Within-Host Evolution Results in Antigenically Distinct GII.4 Noroviruses. <i>Journal of Virology</i> , 2014, 88, 7244-7255.	3.4	60
29	Characterization of Emerging GII.g/GII.12 Noroviruses from a Gastroenteritis Outbreak in the United States in 2010. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3234-3244.	3.9	56
30	Particle Conformation Regulates Antibody Access to a Conserved GII.4 Norovirus Blockade Epitope. <i>Journal of Virology</i> , 2014, 88, 8826-8842.	3.4	54
31	CD300lf is the primary physiologic receptor of murine norovirus but not human norovirus. <i>PLoS Pathogens</i> , 2020, 16, e1008242.	4.7	44
32	GII.4 Human Norovirus: Surveying the Antigenic Landscape. <i>Viruses</i> , 2019, 11, 177.	3.3	43
33	Conformational Occlusion of Blockade Antibody Epitopes, a Novel Mechanism of GII.4 Human Norovirus Immune Evasion. <i>MSphere</i> , 2018, 3, .	2.9	42
34	Characterization of Blockade Antibody Responses in GII.2.1976 Snow Mountain Virus-Infected Subjects. <i>Journal of Virology</i> , 2014, 88, 829-837.	3.4	39
35	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. <i>Science Immunology</i> , 2021, 6, .	11.9	34
36	Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform. <i>Journal of Virology</i> , 2018, 92, .	3.4	33

#	ARTICLE	IF	CITATIONS
37	Chimeric GII.4 Norovirus Virus-Like-Particle-Based Vaccines Induce Broadly Blocking Immune Responses. <i>Journal of Virology</i> , 2014, 88, 7256-7266.	3.4	32
38	Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv084.	0.9	31
39	Emergence of Novel Human Norovirus GII.17 Strains Correlates With Changes in Blockade Antibody Epitopes. <i>Journal of Infectious Diseases</i> , 2017, 216, 1227-1234.	4.0	30
40	Antigenic Characterization of a Novel Recombinant GII.P16-GII.4 Sydney Norovirus Strain With Minor Sequence Variation Leading to Antibody Escape. <i>Journal of Infectious Diseases</i> , 2018, 217, 1145-1152.	4.0	30
41	Human Norovirus Detection and Production, Quantification, and Storage of Virus-Like Particles. <i>Current Protocols in Microbiology</i> , 2013, 31, 15K.1.1-15K.1.45.	6.5	27
42	Identification of Cross-Reactive Norovirus CD4 ⁺ T Cell Epitopes. <i>Journal of Virology</i> , 2010, 84, 8530-8538.	3.4	26
43	Virus-Host Interactions Between Nonsecretors and Human Norovirus. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 10, 245-267.	4.5	24
44	Preadaptation of pandemic GII.4 noroviruses in unsampled virus reservoirs years before emergence. <i>Virus Evolution</i> , 2020, 6, veaa067.	4.9	22
45	Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands. <i>Journal of Virology</i> , 2019, 93, .	3.4	20
46	Impact of Pre-Exposure History and Host Genetics on Antibody Avidity Following Norovirus Vaccination. <i>Journal of Infectious Diseases</i> , 2017, 215, 984-991.	4.0	18
47	Bat Caliciviruses and Human Noroviruses Are Antigenically Similar and Have Overlapping Histo-Blood Group Antigen Binding Profiles. <i>MBio</i> , 2018, 9, .	4.1	18
48	Secretor Status Strongly Influences the Incidence of Symptomatic Norovirus Infection in a Genotype-Dependent Manner in a Nicaraguan Birth Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 105-115.	4.0	18
49	Predicted norovirus resurgence in 2021-2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study. <i>BMC Medicine</i> , 2021, 19, 299.	5.5	18
50	Resolution of diarrhea in an immunocompromised patient with chronic norovirus gastroenteritis correlates with constitution of specific antibody blockade titer. <i>Infection</i> , 2016, 44, 551-554.	4.7	12
51	Human Norovirus Histo-Blood Group Antigen (HBGA) Binding Sites Mediate the Virus Specific Interactions with Lettuce Carbohydrates. <i>Viruses</i> , 2019, 11, 833.	3.3	12
52	Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses. <i>Viruses</i> , 2021, 13, 2033.	3.3	11
53	Production and Clinical Evaluation of Norwalk GI.1 Virus Lot 001-09NV in Norovirus Vaccine Development. <i>Journal of Infectious Diseases</i> , 2020, 221, 919-926.	4.0	8
54	Bile Facilitates Human Norovirus Interactions with Diverse Histoblood Group Antigens, Compensating for Capsid Microvariation Observed in 2016-2017 GII.2 Strains. <i>Viruses</i> , 2020, 12, 989.	3.3	8

#	ARTICLE	IF	CITATIONS
55	Norovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 1267-1289.	4.5	8
56	Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes. <i>Npj Vaccines</i> , 2020, 5, 110.	6.0	6
57	Antigenic Site Immunodominance Redirection Following Repeat Variant Exposure. <i>Viruses</i> , 2022, 14, 1293.	3.3	5
58	A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus. <i>Journal of Virological Methods</i> , 2021, 297, 114196.	2.1	4
59	Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum. <i>Journal of Infectious Diseases</i> , 2022, 226, 1771-1780.	4.0	1